Abstract: OBJECTIVE To evaluate and analyze the rationality and safety of camrelizumab, and provide references for the rational use and management of immune checkpoint inhibitors. METHODS According to the latest regulatory-approved drug labeling, clinical practice guidelines and clinical pathways, the rationality and safety of the cases treated with camrelizumab from January 2019 to December 2020 were analyzed. RESULTS A total of 150 patients were treated with camrelizumab, and as first-line treatment was 54.0%. The clinical application covers 18 tumor types and 86(57.3%) diagnosis were in accordance with the indications of drug labeling and rational use of off-label. There were off-label uses on dose(19.3%), infusion volume(9.3%), order of administration(6%) and pretreatment(14.7%). The incidence of adverse reactions of all-grade and high-grade of camrelizumab was 56.7% and 20.6%, respectively, mainly manifested as blood toxicity(28%), endocrine toxicity(18%) and skin toxicity(14%), etc. One case of bilateral optic disc disease and one case of pulmonary tuberculosis were observed. In routine monitoring, blood routine and biochemical were only 16%. CONCLUSION The clinical application of camrelizumab has problems such as treatment advancement and lack of toxicity monitoring. Based on available evidence, treatment advancement and interchange use of immune checkpoint inhibitors in the absence of evidence-based medicine is not recommended. It is urgent to standardize the management of immune checkpoint inhibitors, especially the rational use of off-label and immune checkpoint inhibitor related toxicities.